DeepScribe vs Danaher Corporation
Side-by-side comparison of AI visibility scores, market position, and capabilities
San Francisco ambient AI scribe using smartphone to listen to patient visits; generates structured EHR notes within minutes, customizable to each physician's documentation style.
About
DeepScribe is a San Francisco-based ambient AI medical scribe company that uses machine learning to listen to physician-patient conversations and automatically generate complete, structured clinical documentation without physician dictation or manual entry. The platform runs on a smartphone placed in the exam room, processes the conversation to identify medically relevant information, and presents a complete draft note in the EHR within minutes of the visit ending. DeepScribe differentiates through its customization capabilities — physicians can train the AI to match their personal documentation style, preferred note templates, and specialty-specific terminology, making the output immediately publishable with minimal editing. The company serves primary care, specialty, and urgent care physicians as well as telehealth providers. Founded in 2017, DeepScribe raised over $30M from investors including Kaiser Permanente Ventures, Greycroft, and SignalFire. The company has demonstrated significant time savings for clinicians and reductions in EHR-related stress. It competes with Suki AI, Nuance DAX, and Freed AI in the ambient medical scribe market.
Washington DC life sciences instruments (NYSE: DHR) at $23.9B FY2024 revenue; Cytiva bioprocessing, Beckman Coulter diagnostics, biopharma destocking recovery, 2025 core revenue +3% guidance competing with Thermo Fisher.
About
Danaher Corporation is a Washington, D.C.-based global science and technology company — publicly traded on the New York Stock Exchange (NYSE: DHR) as an S&P 500 Health Care component — developing, manufacturing, and marketing analytical instruments, reagents, consumables, software, and services for life sciences research, clinical diagnostics, and environmental monitoring through approximately 65,000 employees worldwide. In fiscal year 2024, Danaher reported revenues of $23.9 billion (flat year-over-year) with non-GAAP core revenue declining 1% as the biopharma sector's inventory destocking cycle continued, with Q4 2024 revenue of $6.5 billion (+2.0% reported, +1.0% core) representing an inflection toward recovery, generating $6.7 billion in operating cash flow and $5.3 billion in free cash flow. Danaher guided 2025 core revenue growth of approximately 3% — marking the expected return to growth as biopharma customers who destocked pandemic-era bioprocessing supply surpluses return to normalized purchasing. CEO Rainer Blair leads Danaher's post-spinoff strategy: in September 2023, Danaher separated its Environmental & Applied Solutions segment as Veralto Corporation (NYSE: VLTO), creating two independent public companies — Danaher (pure-play life sciences and diagnostics) and Veralto (water quality and product identification). Danaher's current portfolio centers on bioprocessing (Cytiva's bioreactors, membranes, single-use manufacturing for drug production), clinical diagnostics (Beckman Coulter chemistry and hematology analyzers, Radiometer blood gas analyzers, Cepheid molecular diagnostics), and life sciences research instruments (SCIEX mass spectrometry, Leica Microsystems microscopy).
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.